SKIN at a glance
Beauty Health Co (SKIN, SEC CIK 1818093) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as October 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Beauty Health Co (SKIN) reported revenue of $300.8 million (down 10.0% from FY2024) and a net loss of $9.5 million. Diluted EPS was -$0.16.
- As of September 30, 2026, 19 institutional investment managers tracked by SignalX reported holding Beauty Health Co (SKIN) shares worth $12.1 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $300.8M
- −10.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 19 funds
- $12.1M · −4 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Quarterly revenue $69.2M, down 2.1% YoY from $70.7M
- Gross margin 68.2% vs 64.6% YoY, operating margin 7.2% vs (8.8)%
- Best line Consumables: $50.4M, up 1.2%; weakest Delivery Systems: $18.8M, down 9.9%
- Cash, equivalents and restricted cash $112.4M; nine-month operating cash flow $8.4M vs $22.3M
- Headwinds: macroeconomic and credit conditions, tariffs, geopolitical risks, and $250.0M 2028 Notes requiring refinancing or additional capital
Risk Factors
- Newly added rebranding risk: April 22, 2026 name change may increase marketing costs and weaken customer recognition
- Nasdaq compliance risk: $1.00 bid-price deficiency resolved after October 14, 2026 1-for-20 reverse split
- Delisting risk: another failure within one year could trigger Staff Delisting Determination without a compliance period
- Debt liquidity risk: $250.0 million 2028 Notes exceeded $112.4 million cash, equivalents and restricted cash at September 30, 2026
- Capital markets risk: delisting could trigger 2028 Notes repurchase at principal plus accrued interest
AI summary of the SKIN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Fiscal quarter ended September 30, 2026 results announced November 5, 2026
- Investor conference call scheduled to discuss quarterly financial performance
Item EX-99.1: Item EX-99.1
- Q3 revenue $69.2M, down 2.1%, as delivery-system sales fell to $18.8M from $20.8M
- Consumables returned to growth, reaching $50.4M versus $49.8M, supporting the 37,342-system active install base
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- 1-for-20 reverse split effective October 14, 2026, reducing shares outstanding while proportionally increasing per-share price
- Nasdaq Capital Market trading continues under ticker SKIN, with new CUSIP 88331L306
Item EX-99.1: Item EX-99.1
- 1-for-20 reverse split effective October 14, 2026, with split-adjusted Nasdaq trading under SKIN and new CUSIP 88331L306
- Shares outstanding expected to decline from approximately 130.3 million to 6.5 million, without changing ownership percentages
Item 7.01: Regulation FD Disclosure
- Reverse stock split effective October 14, 2026 at 12:00 a.m. Eastern Time
- Shareholders should expect adjusted share counts and per-share metrics following the split
Item 3.03: Material Modification to Rights of Security Holders
- Item 3.03 points investors to the reverse stock split disclosure under Item 5.03
- Reverse stock split represents a material change to shareholders’ ownership structure and per-share economics
Item 1.02: Termination of a Material Definitive Agreement
- $0 remaining 1.25% convertible senior notes due 2026 after full repayment on September 30, 2026
- Accrued and unpaid interest paid alongside principal, eliminating the associated debt obligation
Item 7.01: Regulation FD Disclosure
- Notes fully retired on September 30, 2026, one day before scheduled October 1 maturity
- $103.235M principal repayment, plus $645,218.75 accrued interest
AI summaries of SKIN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SKIN
Don't miss the next SKIN filing
- Alerts as it files. A push when SKIN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SKIN, by share count.
- Ask anything. An AI agent that reads every SKIN filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Malha Pedro Bruno Ferreira | F | Oct 9, 2026 | 99,742 | $0.55 |
| Malha Pedro Bruno Ferreira | F | Oct 9, 2026 | 78,045 | $0.55 |
| MONAHAN MICHAEL P. | F | Aug 10, 2026 | 32,357 | $0.64 |
| Lewis Sheri | F | Apr 9, 2026 | 24,904 | $0.92 |
| MONAHAN MICHAEL P. | F | Apr 9, 2026 | 26,776 | $0.92 |
| Lewis Sheri | A | Mar 20, 2026 | 746,681 | - |
| Menezes Ronald | A | Mar 20, 2026 | 746,681 | - |
| MONAHAN MICHAEL P. | A | Mar 20, 2026 | 746,681 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $334.3M | $300.8M |
| Gross Profit | - | $182.3M | $196.4M |
| Operating Income | - | -$67.8M | -$20.8M |
| Net Income | - | -$29.1M | -$9.5M |
| Gross Margin | - | 54.5% | 65.3% |
| Op. Margin | - | -20.3% | -6.9% |
| Net Margin | - | -8.7% | -3.2% |
| Balance Sheet | |||
| Total Assets | $929.1M | $685.7M | $499.8M |
| Equity | - | $51.8M | $61.1M |
| ROE | - | -56.2% | -15.6% |
| Per Share | |||
| EPS | - | $-0.36 | $-0.16 |
| Cash Flow | |||
| Operating CF | - | $16.1M | $37.5M |
| CapEx | $3.8M | $756K | $303K |
Source: XBRL data in Beauty Health Co (SKIN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate SKIN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 19 | $12.1M |
| Q2 2026 | 23 | $23.1M |
| Q1 2026 | 26 | $37.8M |
| Q4 2025 | 24 | $61.2M |
| Q3 2025 | 25 | $81.3M |
| Q2 2025 | 25 | $76.8M |
| Q1 2025 | 23 | $42.5M |
| Q4 2024 | 18 | $50.3M |
- Renaissance Technologies LLC+78.3K (+21%)
- Bank of America Corp+7.8K (+11%)
- Citigroup+3.9K (+389400%)
- Millennium Management−2.52M (-33%)
- D.E. Shaw & Co−776.8K (-54%)
- AQR Capital Management−379.5K (-78%)
- BlackRock−123.7K (-1%)
- Citadel Advisors LLC−49.3K (-29%)
- FMR LLC (Fidelity)−10.20M
- T. Rowe Price Group−69.4K
- Franklin Resources−37.5K
- PNC Financial Services−144
Source: 13F-HR filings on SEC EDGAR (aggregated from 183 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SKIN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 8-K | Oct 14, 2026 | - | Analysis | - |
| 4 | Oct 13, 2026 | - | - | - |
| 8-K | Oct 6, 2026 | - | Analysis | - |
| 8-K | Sep 28, 2026 | - | Analysis | - |
| 8-K | Sep 10, 2026 | - | Analysis | - |
| 8-K | Aug 14, 2026 | - | Analysis | - |
| 4 | Aug 12, 2026 | - | - | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| SC 13G | Jul 17, 2026 | - | - | |
| 8-K | Jun 22, 2026 | - | Analysis | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
| 8-K | May 12, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| 8-K | Apr 22, 2026 | - | - | - |
| SC 13G | Apr 20, 2026 | - | - | |
| 4 | Apr 13, 2026 | - | - | - |
| 4 | Apr 13, 2026 | - | - | - |
| 4 | Mar 24, 2026 | - | - | - |
| 4 | Mar 24, 2026 | - | - | - |
| 4 | Mar 24, 2026 | - | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
SKIN SEC filings: frequently asked questions
Which institutions hold SKIN stock?
As of September 30, 2026, the largest Beauty Health Co (SKIN) holders among the 13F filers tracked by SignalX were BlackRock ($5.3 million), Millennium Management ($3.2 million), Vanguard Capital Management LLC ($2.2 million), D.E. Shaw & Co ($413,000), Renaissance Technologies LLC ($279,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SKIN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Beauty Health Co (SKIN) reported revenue of $300.8 million (down 10.0% from FY2024) and a net loss of $9.5 million. Diluted EPS was -$0.16. The figures come from the XBRL data in the 10-K.
What did SKIN report in its latest 8-K?
Beauty Health Co (SKIN) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Fiscal quarter ended September 30, 2026 results announced November 5, 2026.
What are the latest SKIN SEC filings?
Beauty Health Co (SKIN) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on October 13, 2026.
What is SKIN's SEC CIK number?
Beauty Health Co (SKIN)'s SEC Central Index Key (CIK) is 1818093. EDGAR lists every SKIN filing under that number.
Ask anything about SKIN
The research agent reads SKIN's filings, financials, insider trades and 13F holders, then answers with sources.